Datapoint: United Therapeutics to Take On Pulmonary Hypertension With Tyvaso Approval Expansion

With a new FDA approval under its belt, United Therapeutics could have a blockbuster on its hands with the inhaled version of hypertension drug Tyvaso. The drug was approved last week for the treatment of pulmonary hypertension associated with interstitial lung disease. The original version of Tyvaso was approved to treat pulmonary arterial hypertension (PAH) in 2009. For the treatment of PAH, Tyvaso holds covered or better status for 84% of all insured lives under the pharmacy benefit. 5.7% of covered lives have preferred access to Tyvaso without utilization management restrictions.

SOURCE: MMIT Analytics, as of 5/25/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 23

Datapoint: Skyrizi Scores Crohn’s Disease Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 22

Datapoint: Merck-Seagen Deal Could Be in the Works

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 21

Datapoint: Centene Settles New Mexico Medicaid Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today